BioNTech SE (BNTX) Stock: Insider Trades, Congress & Funds

Smart money at a glance

Filings to Nov 14, 2026

Net selling: insiders sold $84.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: -$84.2M net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Sep 30, 2026: 2 added, 1 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about BNTX filings

Are insiders buying or selling BioNTech SE (BNTX) stock?

Net selling: insiders sold $84.2M and bought $0 of BNTX stock on the open market in the 90 days to Nov 14, 2026, according to SEC Form 4 filings. $84.2M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Sahin, Ugur (Chief Executive Officer), who sold $84.2M. The latest filing was on Oct 9, 2026.

Which members of Congress have traded BNTX recently?

None. No member of Congress disclosed a BNTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this BNTX smart-money data?

This summary uses filings available on Nov 14, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Filings could not be loaded.

22 funds hold a position and insiders have been net selling.

Questions about BNTX filings

Are insiders buying or selling BioNTech SE (BNTX) stock?

Which members of Congress have traded BNTX recently?

None. No member of Congress disclosed a BNTX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this BNTX smart-money data?

Funds

What funds are doing

9 moves · 6 mo

Buys/Adds$168.0MSells/Trims$104.5M

Buys/Adds (2)

MW
Marshall Wace
Q3 2026 13F
$27.2M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%
JC
JPMorgan Chase
Q3 2026 13F
$28.5M
added

Sells/Trims (1)

BG
Baillie Gifford
Q3 2026 13F
$53.9M
trimmed
Signals like this: n=7469, 53% finished lower at D15, median -0.5% vs SPY -0.4%

5 more moves

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 5 moves

Other smart money signals

Activist stakes, short interest & more

1 item

SI
Short Interest ChangeModerate
short-volume tape softening: latest 14.1% fell 15.9pp vs 20d avg 30.0%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 3, 2026

Earnings came in 128.2% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 3, 2026

Period ending

Sep 30, 2026

Earnings per share

$1.94+128.24% beat

$0.85 expected

Revenue

EUR 1.29B

SEC filing

Next report

What the street expects next

Estimates as of Nov 9, 2026

EPS expected

-$2.35

-$2.35 to -$2.35

Revenue expected

$500.3M

7 analysts

Last 30 days

0up2down

Analysts cutting estimates

Estimate drift

1.60

Change in 30 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 3, 2026	$1.94est. $0.85	+128.24%beat	EUR 1.29BSEC filing	-15.1%from EUR 1.52B
Jun 30, 2026Reported Aug 4, 2026	-$3.03est. -$2.58	-17.44%miss	EUR 105.6MAlpha Vantage	-59.5%from EUR 260.8M
Mar 31, 2026Reported May 5, 2026	-$1.95est. -$1.92	-1.56%miss	EUR 120.0MAlpha Vantage	-34.3%from EUR 182.8M
Dec 31, 2025Reported Mar 10, 2026	-$0.33est. -$0.25	-33.50%miss	EUR 898.9MAlpha Vantage	-24.5%from EUR 1.19B
Sep 30, 2025Reported Nov 3, 2025	-$0.12est. $0.10	-$0.22miss	EUR 1.52BSEC filing	+22.0%from EUR 1.24B
Jun 30, 2025Reported Aug 4, 2025	-$1.60est. -$1.41	-13.48%miss	EUR 260.8MAlpha Vantage	+102.6%from EUR 128.7M
Mar 31, 2025Reported May 5, 2025	-$1.73est. -$2.35	+26.38%beat	EUR 182.8MAlpha Vantage	-2.6%from EUR 187.6M
Dec 31, 2024Reported Mar 10, 2025	$1.08est. $0.48	+126.56%beat	EUR 1.19BAlpha Vantage	-19.5%from EUR 1.48B

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $86.70
High: $86.97
Low: $84.80
Prev close: $87.65
52-wk high: $124.00
52-wk low: $79.52
Mkt cap: $21.08B
ROE: -8.1%
Fwd P/E: 7.0x
Beta: 1.33
P/S: 8.7x
P/B: 1.1x
Profit margin: -60.9%
Op margin: -55.4%

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -60.9%
Forward P/E: 7.04
Market cap: $21.1B

Valuation

P/S8.71
P/B1.09

Quality

Operating margin-55.4%
ROE-8.1%
ROA-4.0%

Growth

Beta1.33

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

42balanced

20D volatility

34%annualized

52-week range

$85.04

$79.52$124.00

20D support

$84.80recent floor

20D resistance

$92.73recent ceiling

Returns

5D -1.0%20D -5.7%60D -24.8%

Price vs moving averages

SMA20 -3.5%SMA50 -9.0%SMA200 -11.3%

Volume pace

1.01xvs prior 20D

News

What the news says

17 articles · 7 days

Coverage is bullish

13 bullish · 4 neutral · 0 bearish

BioNTech SE Stock 12‑Month Price Target Raised to $115.61, Implies 32% Upside
BullishNov 12
Scholar Rock sells its priority review voucher to BioNTech for $205 million
Leans bullishNov 10
BNTX: BioNTech agrees to buy FDA priority review voucher for $205M
NeutralNov 10
BioNTech (BNTX) agrees to buy a faster FDA review voucher for planned use in a future cancer drug filing.
Leans bullishNov 10
Revenue Beat: BioNTech SE Beat Analyst Estimates By 24%
Leans bullishNov 5
Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Sanofi (OtherSNYNF)
BullishNov 5
Penn-BioNTech Seed Fund Makes First Investment in Emvena Therapeutics to Develop mRNA Treatments for Preeclampsia
BullishNov 4
Penn-BioNTech Innovative Therapeutics Seed Fund Announces First Investment
BullishNov 4

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 3, 2026

$1.94est. $0.85

+128.24%

EUR 1.29BSEC filing

-15.1%from EUR 1.52B

Jun 30, 2026Aug 4, 2026

-$3.03est. -$2.58

-17.44%

EUR 105.6MAlpha Vantage

-59.5%from EUR 260.8M

Mar 31, 2026May 5, 2026

-$1.95est. -$1.92

-1.56%

EUR 120.0MAlpha Vantage

-34.3%from EUR 182.8M

Dec 31, 2025Mar 10, 2026

-$0.33est. -$0.25

-33.50%

EUR 898.9MAlpha Vantage

-24.5%from EUR 1.19B

Sep 30, 2025Nov 3, 2025

-$0.12est. $0.10

-$0.22

EUR 1.52BSEC filing

+22.0%from EUR 1.24B

Jun 30, 2025Aug 4, 2025

-$1.60est. -$1.41

-13.48%

EUR 260.8MAlpha Vantage

+102.6%from EUR 128.7M

Mar 31, 2025May 5, 2025

-$1.73est. -$2.35

+26.38%

EUR 182.8MAlpha Vantage

-2.6%from EUR 187.6M

Dec 31, 2024Mar 10, 2025

$1.08est. $0.48

+126.56%

EUR 1.19BAlpha Vantage

-19.5%from EUR 1.48B

BioNTech SE

Smart money at a glance

What do analysts expect?

Questions about BNTX filings

Questions about BNTX filings

What funds are doing

What insiders are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 128.2% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

What the news says

Ask it in Claude or ChatGPT.

BioNTech SE

Smart money at a glance

What do analysts expect?

Questions about BNTX filings

Questions about BNTX filings

What funds are doing

What insiders are doing

How top traders are positioned

Activist stakes, short interest & more

Unlock everything for $29/month

Earnings came in 128.2% above what analysts expected.

What the street expects next

Previous reports

Is the business strong?

Price structure

What the news says

Ask it in Claude or ChatGPT.

BioNTech SE

Overview

Questions about BNTX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

News

Ask it in Claude or ChatGPT.

BioNTech SE

Overview

Questions about BNTX filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

News

Ask it in Claude or ChatGPT.